早期トリプルネガティブ乳癌に対する術前補助療法:化学療法との併用におけるイパロムリマブおよびツボンラリマブ注射による反応誘導型アプローチ
早期トリプルネガティブ乳癌に対する術前療法:イパロムリマブおよびトゥボンラリマブ注射と化学療法を併用した反応誘導型アプローチ
Iparomlimab and Tuvonralimab Injection (QL1706) is a bifunctional combination antibody targeting both programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4). This is a prospective clinical study that plans to enroll screened, eligible early-stage breast-cancer patients to receive neoadjuvant QL1706 plus chemotherapy (four cycles of TP ± four cycles of AC). After the four TP cycles, imaging and core biopsy will be performed. Patients who achieve radiologic complete response will proceed directly to surgery; those who do not will receive four additional AC cycles before surgery. A key feature is the incorporation of an response-guided neoadjuvant therapy(RGN)model to identify sensitive patients who can forgo anthracyclines, thereby reducing long-term cardiotoxicity.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Yongsheng Jia, Doctor
- 電話番号:+86 18622199359
- メール:yongshengjia@tjmuch.com
研究連絡先のバックアップ
- 名前:Wenxiao Liu
- 電話番号:+86 18515456035
- メール:liuwenxiao2016@outlook.com
研究場所
-
-
-
Tianjin、中国
- 募集
- Tianjin Medical University Cancer Institute & Hospital
-
コンタクト:
- Yongsheng Jia, Doctor
- 電話番号:+86 18622199359
- メール:yongshengjia@tjmuch.com
-
コンタクト:
- Jun Zhang, doctor
- メール:doctorjunzhang@163.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Voluntarily join this study, sign the informed consent form, and demonstrate good compliance;
- Age: 18-75 years old (at the time of signing the informed consent form);
- ECOG PS score: 0-1; expected survival time exceeding 6 months;
- Patients with primary breast cancer confirmed by histopathological or cytological examination;
- Primary tumor diameter > 2 cm as measured by local standard assessment methods;
- Judged by the investigator to meet the American Joint Committee on Cancer (AJCC) 8th edition breast cancer TNM staging criteria as cT2-cT4, cN0-cN3, cM0, with locally advanced or early-stage, unilateral, and histologically confirmed invasive breast cancer;
- According to the latest ASCO/CAP guideline definitions, histopathologically confirmed early-stage triple-negative invasive breast carcinoma meeting all of the following criteria:Tumors are triple-negative on pathological subtyping, defined as: ER-negative: IHC ≤10%; PR-negative: IHC ≤10%; HER2-negative: IHC 0/1+, or IHC 2+ with negative ISH.
- At least one measurable lesion according to RECIST 1.1;
- The patient agrees to undergo breast cancer resection surgery when meeting the surgical criteria after neoadjuvant therapy;
- PD-L1 expression status is known;
- Major organ functions are in good condition;
- Female subjects of childbearing potential must have a negative serum pregnancy test within 3 days prior to the first dose. If a female subject of childbearing potential engages in sexual activity with a non-sterilized male partner, the subject must use acceptable and effective contraception from screening onward and agree to continue these precautions until 12 months after the last dose of the study drug; periodic abstinence and rhythm methods are not acceptable contraceptive methods.
- The subject is willing to provide core needle biopsy tissue samples for research analysis.
Exclusion Criteria:
- Patients with stage IV metastatic breast cancer or other patients deemed by the investigator as unable to achieve curative surgical resection through neoadjuvant therapy;
- Patients with inflammatory breast cancer;
- Patients who have had or currently have other malignancies within the past 3 years. The following two conditions may be eligible: other malignancies treated with a single surgical procedure, achieving continuous 5-year disease-free survival (DFS); cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors [Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invading the basement membrane)];
- Breast cancer patients who have received antitumor therapies such as chemotherapy, endocrine therapy, or immune checkpoint inhibitors within the past 3 years, or who have undergone breast surgery (except diagnostic biopsy for primary breast cancer);
- Patients who have undergone major surgical treatment, incisional biopsy, or significant traumatic injury within 28 days prior to the start of study treatment (except diagnostic biopsy for primary breast cancer);
- Presence of any active autoimmune disease or a history of autoimmune disease;
- Patients currently using immunosuppressants or systemic hormonal therapy for immunosuppressive purposes (at a dose >10 mg/day prednisone or equivalent steroids) and continuing such treatment within 2 weeks prior to enrollment;
- Allergy to any study drug or any component or excipient of the drug;
- Patients with concomitant diseases judged by the investigator as seriously endangering the subject's safety or affecting study completion, or those deemed unsuitable for enrollment for other reasons.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:QL1706 Combination Therapy
neoadjuvant QL1706 plus chemotherapy (four cycles of TP ± four cycles of AC). |
Participants receive QL1706 every 3 weeks (Q3W) + Albumin-bound paclitaxel every 3 weeks (Q3W) + Cisplatin (Q3W) x 4 cycles. After the four TP cycles, imaging and core biopsy will be performed. Patients who achieve radiologic complete response will proceed directly to surgery; those who do not will receive QL1706 Q3W + epirubicin Q3W + cyclophosphamide Q3W x 4 cycles as neoadjuvant therapy before surgery. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
tpCR(ypT0/is ypN0)
時間枠:約27~30週間まで
|
約27~30週間まで
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
放射線学的完全奏効率 (iCR)
時間枠:最大約27~30週間
|
最大約27~30週間
|
|
エピルビシン-シクロホスファミドレジメン使用率
時間枠:約16週間まで
|
約16週間まで
|
|
研究者による評価による無増悪生存期間(EFS)
時間枠:最大約8年
|
最大約8年
|
|
有害事象(AE)を経験した参加者の割合
時間枠:約60週間まで
|
約60週間まで
|
|
全生存期間(OS)
時間枠:最長約8年
|
最長約8年
|
|
健康関連生活の質(HR-QoL)スコア
時間枠:約27〜30週まで
|
約27〜30週まで
|
協力者と研究者
捜査官
- スタディチェア:Yongsheng Jia、Tianjin Medical University Cancer Institute and Hospital
- 主任研究者:Jun Zhang、Tianjin Medical University Cancer Institute and Hospital
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。